PHARMACY

Barr faces lawsuit over Prevacid patent

BY Alaric DeArment

NEW YORK Barr Pharmaceuticals faces a patent infringement lawsuit from three pharmaceutical companies over its application for a generic version of Prevacid.

Three companies, Takeda Pharmaceutical, TAP Pharmaceutical Products and Ethypharm, filed lawsuits in the U.S. District Court of the District of Delaware, alleging that the Montvale, N.J.-based company’s application violated the ‘632 and ‘994 patents.

Takeda, headquartered in Japan, owns the ‘994 patent and has an exclusive license for the ‘632 patent, which France-based Ethypharm owns. TAP, based in Lake Forest, Ill., and now a subsidiary of Takeda America Holdings, has exclusive sublicenses for the patents. The ‘632 patent expires in 2012, while the ‘994 patent expires in 2019.

TAP was a joint venture between Takeda and Abbott that began in 1977 and ended earlier this year. Following the conclusion of the venture, Takeda retained rights to Prevacid, known generically as lansoprazole. Lansoprazole had sales of $550 million in the first quarter of 2008 ending March 31, according to Abbott.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

California information-sharing bill struck down by Assembly

BY Drew Buono

LOS ANGELES A California bill aimed at sharing people’s prescription medication information with mass mailers did not receive a single vote of support in the Assembly Health Committee after being approved by the Senate on May 29, according to the Los Angeles Times. The bill, SB 1096, was written by Sen. Ron Calderon, D-Montebello, who will most likely not reintroduce it, even though he reserved the right to do so.

In presenting the legislation Tuesday, Calderon described it as a boon to consumers, especially those with chronic medical conditions. He said it would allow drugstores to send letters to people reminding them to take their medication or refill a prescription.

The problem with the bill, besides the fact that the patients did not want their prescription medical history shared with someone other than their doctor, is that the bill did not state who would be paying for the reminder letters and which patients would receive them.

According to the Times, it appeared that pharmaceutical companies were behind the funding in an effort to bring in more money on their respective medicines. Also, another provision stated that people who wanted to not be on the mailers would have to opt-out of the program, instead of opting into the program by stating that they would be okay with their information shared.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

CCPA: track-and-trace mandate could cost pharmacies $110,000 per store

BY Alaric DeArment

ALEXANDRIA, Va. Implementing a track-and-trace system would cost drug store chains $84,000 to $110,000 or more per store in the first year, according to a study that examined the safety of the prescription drug supply chain and the potential effects of a federally mandated system.

The study, released by the Coalition of Community Pharmacy Action, examined the safety of the prescription drug supply chain and the potential effects of a federally mandated track-and-trace system. It also found that existing security measures since 2005, including changes in state laws and steps the chains themselves have taken, have already cut the risk of counterfeit drugs entering the supply chain. The study found no cases of counterfeit drugs in the normal distribution channels since 2005, and most of the problems were from Web sites distributing drugs illegally.

The cost estimate was based on costs of computer hardware software, infrastructure, labor and other resources.

The CCPA is comprised of the National Community Pharmacists Association and the National Association of Chain Drug Stores.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?